New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 22, 2014
09:07 EDTSRPTSarepta must enhance dataset for acceptable NDA filing, says Janney Capital
Janney Capital noted that the FDA said Sarepta's current dataset is not strong enough alone to file an adequate NDA for eteplirsen for Duchenne Muscular Dystrophy. The FDA suggested a fourth muscle biopsy in Study 202 patients, but Janney believes the company may be challenged to convince patients to undergo such surgeries. The firm maintains its Sell rating and $10 fair value estimate on shares of Sarepta.
News For SRPT From The Last 14 Days
Check below for free stories on SRPT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 11, 2014
10:20 EDTSRPTNebraska Medical Center not naming Ebola drug, The Street reports
Nebraska Medical Center is not releasing the name of the experimental Ebola drug being given to Dr. Rick Sacra, The Street's Adam Feuerstein reports, citing an emailed response from the hospital. Traders are speculating Tekmira (TKMR) is the manufacturer of the drug, Feuerstein points out. Sarepta (SRPT) disclosed that it is not involved in the treatment of Sacra, added Feuerstein. Shares of Tekmira are up 3% to $19.65 in morning trading. Reference Link
September 4, 2014
13:17 EDTSRPTSarepta rises after FDA seeks comment on proposed DMD drug guidance
Subscribe for More Information
12:54 EDTSRPTSarepta strength attributed to circulation of DMD guidance document
Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use